Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction

• Status: Terminated
• Trial end date: 2018-03-08
• Target enrollment: 0
• Participant gender: Female

Summary

This study will evaluate the efficacy of analgesia provided by liposomal bupivacaine (Exparel) when compared to bupivacaine HCL as a transverse abdominis plane (TAP) block in terms of discharge milestones, opioid use, costs, and patient-reported satisfaction at 12, 24, and 72 hours. The investigators propose that Exparel will lower opioid use, length of stay, and overall cost of abdominally-based autologous breast reconstruction, and will lead to greater patient satisfaction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Analgesics; Bupivacaine

Criteria

Inclusion Criteria:

• Scheduled for abdominal-based autologous breast reconstruction (DIEP, MS-TRAM, or TRAM).

• At least 18 years of age.

• Female.

• Able to understand and willing to sign a written informed consent document.

Exclusion Criteria:

• Cognitive impairment.

• History of abdominal surgery precluding free flap donor site.

• Allergy or intolerance to bupivacaine or "amide" anesthetics.

• Significant preoperative chronic pain (requiring daily narcotics) or neuropathic pain (requiring daily use of pregabalin or gabapentin) within the previous 3 months.

• Pregnant or breastfeeding.